4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:原厂直采,平行进口,授权代理(蚂蚁淘为您服务)
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Cell_lysis > 室内生物技术/天然Bet v 1(NA-BV1-1)/1/NA-BV1-1
商品详细室内生物技术/天然Bet v 1(NA-BV1-1)/1/NA-BV1-1
室内生物技术/天然Bet v 1(NA-BV1-1)/1/NA-BV1-1
室内生物技术/天然Bet v 1(NA-BV1-1)/1/NA-BV1-1
商品编号: NA-BV1-1
品牌: inbio
市场价: ¥12100.00
美元价: 6050.00
产地: 美国(厂家直采)
公司:
产品分类: 细胞裂解和提取物
公司分类: Cell_lysis
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
Allergen:nBet v 1 (Betula pendula allergen 1), European white birch
Unit:250µg
Source:

Birch pollen (Betula pendula)

Mol. Wt:18 kDa
Purification:

From birch pollen extract by multi-step chromatography.

Purity > 95 % by silver stained SDS-PAGE

Concentration:

See product insert.

Formulation:

Preservative-free and carrier-free in phosphate bufferedsaline, pH 7.4. Sterile filtered.

Storage:

Store at -20ºC. Avoid repeated freeze-thaw cycles.

Notes:

Purified natural Bet v 1 appears as a triplet of 18-20kD proteins representing distinct isoforms of Bet v 1 (1).

PDB:
Product Resources:Natural Bet v 1 Certificate of Analysis
Allergens are provided for research and commercial use in vitro: not for human in vivo or therapeutic use.
References:
  1. Batard, T. et al: Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int Arch Allergy Immunol 2005, 136 (3), 239-249.
  2. Breiteneder, H.et al: The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 1989, 8 (7), 1935-1938.
  3. Spangfort, M. D.et al:Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol 2003, 171 (6), 3084-3090.
  4. Swoboda, I.et al: Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 1995, 270 (6), 2607-2613
  5. Vieths, S et al.: Establishment of recombinantmajor allergens Bet v 1 and Phl p 5a as Ph. Eur. Reference standardsand validation of ELISA methods for their measurement. Pharmeuropa Bio & SN 2012; 118-13.
品牌介绍
indoor biotechnologies由前弗吉尼亚大学医学和微生物学教授,UVA哮喘和变态反应中心的成员Martin D. Chapman博士创立。Chapman博士是美国过敏,哮喘和免疫学研究院的院士,并曾担任美国国立卫生研究院,环境保护署,学术机构和《财富》 500强公司的顾问。室内生物技术专业生产抗过敏和哮喘的生物制剂。该公司是评估家庭,工作场所,学校和商业建筑中过敏原环境暴露的全球领导者。该公司生产用于过敏研究和诊断的高纯度过敏原,并在过敏原结构,功能和免疫识别方面的研究获得国际认可。室内生物技术的使命是改善过敏和哮喘患者的生活质量。